Navigation Links
Dry Powder Inhalation: Devices, Drugs, Therapeutics, Markets and Forecasts
Date:8/1/2011

NEW YORK, Aug. 1, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Dry Powder Inhalation: Devices, Drugs, Therapeutics, Markets and Forecasts

http://www.reportlinker.com/p0581176/Dry-Powder-Inhalation-Devices-Drugs-Therapeutics-Markets-and-Forecasts .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology

Advances in drug formulation and inhalation device design are creating new opportunities for inhaled drug delivery as an alternative to oral and parenteral delivery methods. Much of the interest in pulmonary delivery of systemic drug therapies is focused on chronic diseases and refractory conditions – aliments that require frequent drug administration for a protracted period of time. While several approaches for delivering active substances to, and systematically via, the lungs compete in this space, recent advances and investment in powder formulations, particle engineering, and device architecture have positioned dry powder inhalation (DPI) as a formidable challenger to more established pulmonary methods such as metered dose inhalers and nebulizers. While evolving DPI technology and combination therapeutic products continue to have a significant impact on the treatment of upper respiratory diseases and conditions, dry powder inhalers are making strides in applications requiring the systemic delivery of both small and large molecule and engineered macromolecules for the treatment of a range of pathologies.

Highlights

• Analyzes and evaluates Dry Powder Inhalers and competing inhaled drug delivery technologies and assesses the market potential for existing and probable future products

• Examines Dry Powder Inhaler design issues and evolving market factors

• Forecasts the impact of DPI technology and devices on drug delivery markets and projects probable future developments

• Provides forecasts of DPI combination product demand by indication and drug class to 2014

• Profiles Dry Powder Inhalation market participants, their technology, product development activity, and business strategies

Executive Summary

The Market Picture for Inhaled Therapeutics

Devices, Formulations and Market Evolution

Established Therapeutic Targets

Emerging Therapies

Demographics and Growth

Competing Technologies

Market Drivers

Risk Factors

Dry Powder Inhalation Technology

Dry Powder Formulations

Dry Powder Particle Technology & Powder Engineering

Dry Powder Formulations

Dry Powder Processing

Dry Powder Packaging

Emerging Formulations

Dry Powder Inhalers

DPI Device Characteristics

DPI Design Parameters

DPI Device Assessments

Acu-Breathe (Respirics)

Aerolizer Novartis)

AIR (Civitas/Alkermes)

Airmax (Teva)

Aspirair (Vectura)

Axahaler (S.M.B.)

Breezhaler (Novartis)

Clickhaler (Vectura)

Conix Dry (3M)

Cricket (Mannkind)

Cyclohaler (Teva)

Diskhaler (GlaxoSmithKline)

Diskus (GlaxoSmithKline)

Dreamboat (Mannkind)

Easyhaler (Orion)

EZ Aer (Aerovance)

Flexhaler (AstraZeneca)

Genuair (Almirall)

Gemini (GSK)

Handihaler Boehringer Ingelheim)

MicroDose (MicroDose Therapeutx)

Next DPI (Chiesi)

Novolizer (Meda)

Oximax (Mantecorp)

Podhaler (Novartis)

Pulmojet (sanofi-aventis)

Pulvinal (Chiesi)

Skyehaler (SKyepharma)

Solis (Sandoz/Novartis)

Taifun (Akela)

Taper Dry (3M)

Trivair (Trimel Bipharma)

Twincaps/Flowcaps (Hovione)

Twisthaler (Schering /Merck)

Turbuhaler (AstraZeneca)

Dry Powder Inhalation – Therapeutic Segment Analysis & Forecasts

Upper Respiratory Indications

Disease Segments

Therapeutic Landscape

Prescribing Trends and Growth Factors

Systemic Drug Delivery

Bioterror

Diabetes

Hereditary Diseases

Cystic Fibrosis

Infectious Diseases

Osteoporosis

Neurology

Pain Management

Market Factors

Device Design

Regulatory Issues

Patient Compliance

The Role of CMOs/CSOs

Healthcare Economics

Company Profiles

To order this report:

Drug Delivery Technology Industry: Dry Powder Inhalation: Devices, Drugs, Therapeutics, Markets and Forecasts

Drug Delivery Technology Business News

More  Company Profile, SWOT and Revenue Analysis!

CONTACT
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
2. Data Show Aerovances Aerovant(TM) Inhalation Powder is Well Tolerated in Asthma Patients
3. ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients
4. New Powder Speeds Healing of Difficult Foot Wounds
5. Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lees Pharmaceuticals
6. FDA Grants Bayer HealthCare Pharmaceuticals Orphan Drug Designation for Investigational Ciprofloxacin Dry Powder Inhaler for the Treatment of Cystic Fibrosis
7. Hoviones TwinCaps(R) Dry-powder Inhaler Approved in Japan as Part of Inavir(R) Influenza Treatment
8. FDA Approves Pharmaxis ARIDOL™ (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
9. Reportlinker Adds Dry Powder Inhalation
10. Pharmaxis Launches ARIDOL® (Mannitol Inhalation Powder) Bronchial Challenge Test Kit for the Assessment of Bronchial Hyperresponsiveness
11. RSB Spine, LLC, Announces Distribution Agreement with Paradigm BioDevices, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Feb. 16, 2017 Research and Markets ... Emerging Medical Device Technologies" report to their offering. ... Traditional ... procedures, general instruments, non-drug coated implantables, large endoscopes, needle based ... use over the last two to three decades for the ...
(Date:2/16/2017)... Inc. (NYSE: DVA ) today announced results for ... Net income attributable to DaVita Inc. for the quarter ... $0.80 per share and $880 million, or $4.29 per share, ... Inc. for the quarter and year ended December 31, 2016, ... $0.98 per share, and $789 million, or $3.85 per share, ...
(Date:2/16/2017)... 2017  Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ... announced that executive management will participate in the RBC ... 22-23, 2017. Adrian Adams , Chief Executive Officer, ... p.m. local time on Wednesday, February 22, 2017. ... event may be accessed from the Investors section of ...
Breaking Medicine Technology:
(Date:2/17/2017)... TN (PRWEB) , ... February 17, 2017 , ... ... Inc. (ISTS) brings its educational assistance management solution to the exhibit floor for ... Center in Orlando, Fla. , From Feb. 19–23, 2017, more than 40,000 ...
(Date:2/17/2017)... Church, VA (PRWEB) , ... February 17, 2017 ... ... Implementing the Steps to Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, ... , Do manufacturers distinguish between corrective action (CA) and preventive action (PA)? ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... season , Trinity Health and the U.S. Soccer Foundation announced today that they ... underserved communities. Soccer for Success, the Foundation’s soccer mentoring program, teaches kids the ...
(Date:2/17/2017)... CA (PRWEB) , ... February 17, 2017 , ... ... that their Chief Executive Officer, George Rogers, was named to Staffing Industry Analysts' ... The Staffing 100 honors those who have made notable contributions to the staffing ...
(Date:2/17/2017)... CO (PRWEB) , ... February 17, 2017 , ... Top ... annual International Healing NET Foundation Summit from February 21 - 23 in Beaver Creek, ... Foundation (HNF). This marks the Summit’s second year in Beaver Creek, hosting over 60 ...
Breaking Medicine News(10 mins):